Beyond Air, Inc. - Common Stock (XAIR)

Competitors to Beyond Air, Inc. - Common Stock (XAIR)

Aeris Health, Inc. 

Beyond Air, Inc. and Aeris Health, Inc. are similar in that they are both focused on developing therapies for respiratory conditions, which places them in direct competition. Aeris is concentrating on developing solutions to improve air quality and lung health through various delivery systems. Beyond Air, however, has a more concentrated product that focuses on the delivery of nitric oxide, which has shown substantial efficacy in clinical trials. Currently, Beyond Air appears to have a competitive advantage by already being further along in its regulatory process, effectively positioning itself in the marketplace.

AviBioPharma, Inc.

Beyond Air, Inc. and AviBioPharma, Inc. both operate in the biotechnology sector, focusing on innovative therapies. They compete primarily in the development of treatments utilizing gas therapies and delivery systems for respiratory conditions. While Beyond Air has significantly advanced in the nitric oxide delivery system for respiratory issues, AviBioPharma is leveraging its expertise in gene therapy approaches, creating a diverse strategy that can appeal to a different segment of patients. The competitive edge seems to favor Beyond Air due to its existing product pipeline and established clinical validation.

Harrow Health, Inc. 

Harrow Health, Inc. and Beyond Air, Inc. compete through their focus on innovative treatment solutions for health conditions. Harrow specializes in ophthalmic pharmaceuticals, while Beyond Air has a niche in respiratory therapies, specifically nitric oxide delivery for the treatment of lung diseases. Although both companies are targeting distinct market needs, competition arises in their ability to secure market share and healthcare provider endorsements. Beyond Air holds a competitive advantage due to its focused approach on respiratory conditions and an established presence in clinical trials, giving it a strong footing in its chosen specialty.

TFF Pharmaceuticals, Inc. 

TFF Pharmaceuticals, Inc. competes with Beyond Air, Inc. in the realm of novel pharmaceutical delivery systems. Both companies seek to innovate in their respective fields, where TFF specializes in thin film formulations for drug delivery, while Beyond Air focuses on gaseous drug delivery for respiratory diseases. This competition is characterized more by the differing methodologies of drug delivery rather than direct therapeutic competition since their applications target different administration routes. Beyond Air currently holds an advantage due to its advanced development stage and recognized therapeutic applications in severe respiratory conditions.